Balance sheet as of December 31, 2010

Profit and loss account year ended December 31, 2010

Introduction

In 2010, Alzheimer Europe had an audited income of EUR 1.188,868.67 of which EUR 641,024.92 (53.92%) were for the organisation’s core activities (including the organisation’s Dementia Ethics Network and Annual Conference), EUR 237,843.75 (20.01%) were for the organisation’s public affairs activities and EUR 310,000 (26.08%) for the organisation’s “Value of diagnosis” project..

Funding of core activities (EUR 641,024.92)

In 2010, the core funding of Alzheimer Europe was composed as follows:

• EUR 304,012.74 (47.43%) from public funding,
• EUR 181,029.77 (28.24%) from member organisations,
• EUR 78,203.28 (12.20%) from individuals,
• EUR 39,329.54 (6.14%) from corporate sources,
• EUR 26,800 (4.18%) from foundations and other non-profit organisations,
• EUR 8,568.93 (1.34%) from other sources and
• EUR 3,080.66 (0.48%) from bank interest and similar.

Public funding

In 2010, the breakdown of public funding totalling 304,012.74 can be broken down as follows:

• Alzheimer Europe received EUR 250,000 as an operating grant from the European Commission and 21,192 for its participation in the PharmaCog project
• EUR 13,692.95 was received from the Social Security administration in Luxembourg,
• EUR 10,350 from Luxembourg Congrès as a contribution to the rent of the conference centre for the 20^th AE Conference in Luxembourg and
• EUR 8,777.79 from the German Ministry of Health to cover the expenditure of some of the running costs of European Dementia Ethics Network.

Funding from member organisations

In 2010, the EUR 181,029.77 funding from member organisations can be broken down as follows:

• EUR 93,045.53 from the Luxembourg member organisation through the secondment of the AE Executive Director,
• EUR 53,150 in membership fees,
• EUR 12,000 from the Luxembourg member organisation by providing the offices of Alzheimer Europe free of rent,
• EUR 6,134.24 in co-financing from member organisations covering the travel expenses of AE Board members to attend Board meetings,
• EUR 17,700 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Individuals

In 2010, AE received EUR 78,203.28 from individuals which can be broken down as follows:

• EUR 65,700 in conference registrations,
• EUR 12,240.10 in publication sales and
• EUR 263.18 in donations.

Corporate support

In 2010, Alzheimer Europe received EUR 39,329.54 from corporate sources as core-funding which can be broken down as follows:

• EUR 10,867.36 from Elan as support to the Alzheimer Europe Conference in Luxembourg,
• EUR 10,000 from Pfizer as support to the Alzheimer Europe Conference in Luxembourg,
• EUR 7,500 from Nutricia as support to the Alzheimer Europe Conference in Luxembourg,
• EUR 5,000 from Novartis as support to the Alzheimer Europe Conference in Brussels,
• EUR 3,000 from Mazars which carried out the audit of the organisation’s accounts free of charge and
• Huntsworth Health contributed EUR 2,962.18 in travel support and honoraria.

Foundations and organisations

The EUR 26,800 which Alzheimer Europe received in 2010 from foundations and other non-profit organisations can be broken down as follows:

• EUR 5,000 from Fondation Médéric Alzheimer and Fondation Roi Baudouin to support the Alzheimer Europe Conference in Brussels,
• EUR 9,000 from Fondation Médéric Alzheimer to support the legal rights project of Alzheimer Europe.

Bank interest and similar

In 2010, Alzheimer Europe had an income of EUR 3,080.66 from bank interest and similar income.

Other income

In 2010, EUR 8,568.93 came from other sources not mentioned above.

Funding of public affairs activities (EUR 237,843.75)

In 2010, Alzheimer Europe received EUR 237,843.75 for its public affairs activities, of which

• EUR 213,210.37 (89.64%) came from corporate sponsors,
• EUR 22,918.74 (9.64%) from reserves brought forward from the financial year 2008,
• EUR 1,012.80 (0.43%) from other income and
• EUR 701.84 (0.30%) from public sources.

Corporate support

The corporate support received by Alzheimer Europe for its public affairs activities can be broken down as follows:

• Pfizer, Janssen-Cilag and Novartis each contributed EUR 40,000 as a gold sponsor,
• GlaxoSmithKline contributed EUR 35,638 as a gold sponsor,
• Lundbeck and Lilly contributed EUR 20,000 each as silver sponsors,
• Elan contributed EUR 10,072.37 as a bronze sponsor and
• Nutricia provided EUR 7,500 in support.

Reserves

In 2010, Alzheimer Europe was able to contribute EUR 22,918.74 of its own reserves to its public affairs activities which came from income received on account in 2009.

Public funding

In 2010,

• EUR 701.84 was received from the Social Security administration in Luxembourg,

Other income

In 2010, EUR 1,012.80 came from sources not included above.

Funding of Value of Diagnosis-project (EUR 310,000)

In 2010, AE received an educational grant of EUR 310,000 from Bayer Healthcare for its Value of Diagnosis project.

Overall funding

The following table lists all sources of income received in 2010. In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.